Kornimate/medical-research-clean huggingface dataset:
laser treatment of acne scars in fitzpatrick skin types iii-vi

Conditions: Acne Scars

Summary: the purpose of this study is to evaluate the revlite q-switched neodymium: yttrium-aluminum-garnet (nd:yag) laser in the treatment of acne scars in darker skin types (fitzpatrick skin types iii, iv, v and vi).


Eligibility criteria:
inclusion criteria: * 18 years or older with fitzpatrick skin type iii, iv, v or vi * evidence of atrophic scarring exclusion criteria: * pregnancy, lactating or planning to become pregnant during the study * history of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis * any skin pathology or condition that could interfere with the evaluation or requires the use of interfering topical or systemic therapy * any condition which, in the investigator's opinion, would make it unsafe for the subject to participate * currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days prior to entering the study * subject is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function * subject may be unreliable for the study. this includes subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits * use of oral or topical isotretinoin therapy within 6 months prior to enrollment. with the exception of isotretinoin, subjects will be allowed to continue their topical or oral acne medications during the trial * need to be exposed to artificial tanning devices or excessive sunlight during the trial * prior treatment with parenteral gold therapy * diabetes type i or ii, lupus, scleroderma or a similar immune system disorder * subject does not agree to refrain from any other type of facial skin resurfacing (e.g., microdermabrasion, laser or ipl treatment, chemical peel) or injected filler/other substances (e.g., restylane, botox) that might affect the treatment area for the duration of the study * underlying silicone or other nonabsorbable fillers in the treatment area or has had filler (e.g., collagen, fat) injections within the past 3 months * history of keloidal scarring or nodulocystic acne * phenol or chemical peel or dermabrasion to the the treatment area within the past 6 months
international hiv antiretroviral adherence, resistance and survival

Conditions: HIV/AIDS

Summary: real-time wireless adherence monitoring to hiv antiretroviral therapy in rural uganda.

the investigators will study use a novel method of real-time wireless adherence monitoring in one of the best established multi-disciplinary hiv antiretroviral treatment cohorts in rural africa. the investigators will advance our theoretical understanding of hiv antiretroviral adherence behavior, hiv pathogenesis, and to address the monitoring and prevention of hiv antiretroviral treatment failure. based on a successful pilot study in rural uganda and favorable cost-effective estimates, the investigators will deploy the wisepill real-time wireless adherence monitoring system to objectively monitor adherence in real time. the investigators will determine to what extent social capital mitigates economic barriers to long-term adherence and determine if the pervasive impact of stigma on adherence operates through social capital (aim 1). the investigators will determine the relationship between missed doses, low-level viremia (between 1 and 50 copies rna/ml), inflammation, bacterial translocation, suboptimal cd4 response, and mortality (aim 2). finally, the investigators will examine the relationship between complex adherence patterns and viral failure to both inform selective viral load monitoring and to lay the foundation for the first-of-kind intervention to prevent viral failure after missed doses, but before viral rebound (aim 3). the investigators will secure behavioral and biologic data over nine years of potential treatment by recruiting 500 additional people to our existing cohort in mbarara, uganda for a total of 750 participants.

Eligibility criteria:
inclusion criteria: * hiv positive patients over 18 years * art naive and initiating therapy at the mbarara immune suppression syndrome (iss) clinic * live within 60 kilometers of the clinic * women who have received a single dose of nevirapine for prevention of mother to child transmission, but have not received other art, will be included exclusion criteria: * patients who do initiate therapy during the course of the study recruitment * patients who decline or are unable to give consent

Keywords: hiv/aids in resource limited setting hiv treatment outcomes in resource limited setting adherence to hiv treatment in resource limited setting art resistance in resource limited setting
comparison between patching and interactive binocular treatment (ibittm) in amblyopia

Conditions: The New Treatment in Amblyopia Therapy

Summary: the purpose of this study is to investigate the effect of amblyopia therapy on cases who will receive interactive binocular treatment (ibittm) without patching compared with those who will receive standard patching of the dominant eye with placebo ibittm. in this randomized clinical trial, 40 unilateral amblyopic children (3 to 10 years old) will be studied. all unilateral functional amblyopic children with best corrected visual acuity (bcva) worse than 0.30 logmar at least in one eye or a difference of two bcva lines of snellen between the two eyes will be included and randomly will divide into the case (n=19) and control (n=21) groups. cases will play i-bit™ games, while controls will have standard patch therapy and will play with placebo ibittm for one month. all subjects will be underwent comprehensive ophthalmic examinations at baseline and at one-month follow-up.


Eligibility criteria:
inclusion criteria: * functional amblyopia with bcva less than 20/30 (0.3 logmar) at least in one eye * a difference of two bcva lines of snellen between the two eyes exclusion criteria: * a history of penalization one month prior to the study * bilateral amblyopia * bcva less than 20/200 * eccentric fixation * nystagmus * ocular deviation more than 10 prism diopter (pd) * organic amblyopia * uncooperative children those with * mental and physical disability * systemic diseases
hydroxychloroquine in prevention of preeclampsia

Conditions: Preeclampsia

Summary: pre-eclampsia complicates up to 8% of pregnancies and is a major contributor to maternal mortality and morbidity the only effective treatment is delivery, which leads to significant neonatal morbidity and mortality if carried out preterm, especially when the disease occurs early in pregnancy. vascular endothelial dysfunction and immunological impairment are associated with preeclampsia. to date, there is no effective or optimal therapeutic approach for these conditions. hydroxychloroquine has endothelial protective action via ant diabetic, lipid lowering, antioxidant effects or direct endothelial protection. hydroxychloroquine is an antimalarial and immunomodulatory agent. in pregnancy, hydroxychloroquine is prescribed for inflammatory conditions associated with adverse perinatal outcomes such as systemic lupus erythematosus, antiphospholipid syndrome and placental inflammatory lesions such as chronic histiocytic intervillositis, hydroxychloroquine has therapeutic potential to improve placental function in pregnancies associated with heightened inflammation.


Eligibility criteria:
inclusion criteria: 1. pregnant women in 1st 6 weeks gestation. 2. history of preeclampsia in previous pregnancies. 3. women who accepted to participate exclusion criteria: 1. risk factors (multiple gestation, chronic hypertension, chronic renal disease). 2. known contraindication to a treatment by hcq (retinopathy, hypersensitivity to chloroquine or hcq, g6pd deficiency, chronic liver or kidney insufficiency, heart block, significant chronic digestive, hematologic disease epilepsy or psychotic disorders.) or disorder of lactose metabolism 3. patient already using hcq (rheumatoid arthritis, lupus, solar eczema). 4.impossible for follow up
regulatory post marketing surveillance study in korea

Conditions: Endometriosis

Summary: the objective of the study is to investigate and collect post marketing data on the safety and efficacy of visanne at follow-up visit after about 6 months of treatment and - for a subset of patients - at optional long-term follow-up visit after about 1 year of treatment under daily practice treatment conditions in korean women and to obtain data on drug utilization on treatment for endometriosis.


Eligibility criteria:
inclusion criteria: * signed and dated informed consent * women diagnosed by a physician as having endometriosis * women who are prescribed visanne(dienogest 2mg)for the first time during the study period exclusion criteria: - all contraindications according to the local marketing authorization have to be considered.
study on astra tech implant system, osseospeed™ implants in patients missing all teeth in the upper jaw, restored with provisional teeth within 24 hours

Conditions: Jaw, Edentulous

Summary: the purpose of the study is to evaluate astra tech implant system, osseospeed™ implants, in patients with totally edentulous upper jaws and poor bone quality and quantity, when provisional artificial teeth are attached within 24 hours. the primary objective is to investigate implant survival rate.


Eligibility criteria:
inclusion criteria: * provision of informed consent * aged 20 years and over * history of totally edentulous maxilla of at least three months * radiographic finding indicating bone quality class 3 or 4 (lekholm and zarb) in the maxilla * radiographic finding indicating bone quantity class c, d or e (lekholm and zarb) in the maxilla * presence of natural teeth, partial prosthesis and/or implants in the mandible, within positions 35-45 (according to the fdi digit system) * deemed by the investigator as likely to present an initially stable implant situation suitable for immediate loading. exclusion criteria: * unlikely to be able to comply with study procedures, as judged by the investigator * uncontrolled pathologic processes in the oral cavity * known or suspected current malignancy * history of radiation in the head and neck region * history of chemotherapy within 5 years prior to surgery * systemic or local disease or condition that would compromise post-operative healing and/or osseointegration * uncontrolled diabetes mellitus * corticosteroids or any other medication that would compromise post-operative healing and/or osseointegration * history of bone augmentation in the maxilla within 6 months prior to surgery * known pregnancy at time of enrolment * present alcohol and/or drug abuse * current use of tobacco or history of tobacco use within 6 months prior to surgery * need for interpreter

Keywords: jaw, edentulous (maxilla, with poor bone quality and quantity)
subcutaneous botulinum toxin for cutaneous allodynia

Conditions: Pain

Summary: superficial injection of botulinum toxin has been advocated for cosmetic purposes but has also been reported to be helpful for some pain conditions. the investigators have observed prolonged profound analgesia following subcutaneous superficial injection of botulinum toxin type a (bta) in patients with certain types of neuropathic pain. the investigators propose to study if addition of bta extends pain relief compared to placebo when injected subcutaneously into areas of cutaneous allodynia (the property that a normally non-noxious stimulus is perceived as painful).

post-surgical neuromatous pain patients have marked cutaneous allodynia. touching their skin with normally non-painful stimuli results in pain. injected local anesthetics are often effective in providing temporary relief. in the course of clinical practice the investigators have observed that a number of patients with cutaneous allodynia have had marked persistent benefit from subcutaneous injection of botulinum toxin type a. rather than killing targeted neurons, botulinum toxin type a inhibits release of acetylcholine from cholinergic nerve terminals in a prolonged but ultimately reversible manner. neuropathic pain and its hallmark allodynia are classically difficult to treat. standard treatment with tricyclic antidepressants, anti-epileptic drugs, opiates and spinal cord stimulation is frequently disappointing leaving patients with refractory pain. surgical or percutaneous ablation of involved nerves has fallen out of favor among many due to disappointing results. a pilot study is needed to assess the efficacy of superficially injected botulinum toxin type a for treatment of cutaneous allodynia and spontaneous pain among patients with neuropathic pain.

Eligibility criteria:
inclusion criteria:- moderate to severe pain (greater than 4/10) of duration more than 6 months despite previous therapy. * the patient exhibits at least 80% pain relief following injection of local anesthetic subcutaneously into scar as assessed by change in nrs * the patient reports the presence of hyperalgesia, allodynia, dysesthesia, or hypoesthesia surrounding the scar * age 18-100 * ability to read, write, and converse in english, provide informed consent, and follow study procedures exclusion criteria: 1. any neuromuscular disorder such as myasthenia gravis, eaton lambert, muscular dystrophy 2. any ongoing legal action related to their pain 3. allergy to local anesthetics 4. a current or history of any severe psychiatric disorder 5. history of any adverse reaction to botulinum toxin 6. history of botulism 7. untreated infection 8. coagulopathy 9. females - positive pregnancy test 10. surgery within the past 6 months at the site of the painful scar
a study of nipocalimab administered to adults with generalized myasthenia gravis

Conditions: Myasthenia Gravis

Summary: the purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gmg).


Eligibility criteria:
inclusion criteria: * diagnosis of myasthenia gravis (mg) with generalized muscle weakness meeting the clinical criteria for generalized myasthenia gravis (gmg) as defined by the myasthenia gravis foundation of america (mgfa) clinical classification class ii a/b, iii a/b, or iva/b at screening * myasthenia gravis - activities of daily living (mg-adl) score of greater than or equal to (\>=) 6 at screening and baseline * has sufficient venous access to allow drug administration by infusion and blood sampling as per the protocol * a woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin \[beta-hcg\]) at screening and a negative urine pregnancy test at day 1 prior to administration of study intervention * a male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum 90 days after receiving the last administration of study intervention exclusion criteria: * has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her gmg, or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant * has mgfa class i disease or presence of mg crisis (mgfa class v) at screening, history of mg crisis within 1 month of screening, or fixed weakness (and/or 'burnt out' mg) * has had a thymectomy within 12 months prior to screening, or thymectomy is planned during the study * has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients * has experienced myocardial infarction, unstable ischemic heart disease, or stroke within 12 weeks of screening
comparison of a novel non-invasive, non-touch infrared thermometer with routine thermometry in routine clinical practice

Conditions: Healthy; Febrile

Summary: quantify the reliability and agreement of estimated core body temperature using the instatemp md™ and other widely marketed reference thermometers

this is a cross sectional clinical investigation in order to quantify the reliability and agreement of estimated core body temperature using emitted surface body heat measured by the instatemp md™ non-touch thermometer when compared to other widely marketed reference thermometers

Eligibility criteria:
inclusion criteria: 1. any age 2. either gender 3. attending ed, outpatients or inpatient departments of cork university hospital campus 4. provision of informed consent or in case of minor's provision of age appropriate assent with informed consent of parent (legal guardian). exclusion criteria: 1. those who in the opinion of the researcher are too agitated, distressed or who are otherwise unable to cooperate with study procedures 2. those who forehead cannot be fully exposed to the ambient conditions for at least 15 minutes 3. those with signs or recent history of inflammation or infection of the forehead or at the reference clinical test site 4. subjects currently using cooling blankets or fans. 5. subjects currently receiving treatment with thyroxine, barbiturates, antipsychotics, corticosteroids, alcoholic intoxication, documented illicit drug use or immunizations in the previous 5 days 6. any recent hot or cold drinks prior to a sub-lingual reading (i.e. 15min before measurement) 7. those participating in a clinical trial of an investigational medicinal product
ihscs with the gene correction of hbb intervent subjests with β-thalassemia mutations

Conditions: Thalassemia

Summary: this is a single centre、single arm、open-label study，to investigate the safety and efficacy of the gene correction of hbb in patient-specific ihscs using crispr/cas9.

the purpose of this study is to evaluate the efficacy and safety of transplantation ihscs intervent subjests with β-thalassemia mutations.

Eligibility criteria:
inclusion criteria: 1. subjects ≥ 2 and ≤ 60 years of age 2. subjects was confirmed the transfusion-dependent β-thalassemia 3. adequate organ function, as defined by: serum creatinine ≤ 1.5 mg/dl ； serum alt/ast）≤2.5×uln；alb≥25g/l； serum total bilirubin \< 1.5x uln left ventricular ejection fraction≥50% 4. chest x-ray and ecg test results were normal, no serious cardiopulmonary diseases 5. subjects survival was expected≥6 months 6. adult patients were willing to use reliable contraceptives (such as condoms) and not to donate sperm throughout the study period and within three months of discharge 7. subjects and the guardians able to undergo post-physical therapy/rehabilitation exclusion criteria: 1. subjects allergic to macromolecular biological agents such as antibodies or cytokines 2. subjects receipt of any investigational clinical trials within 3 months. 3. subjects previous treatment with any hematopoietic stem cell transplantation or other organ transplantation 4. uncontrolled bleeding symptoms 5. severe cardiovascular disease is known, including any of the following: myocardial infarction or thrombosis has occurred in the past six months subjects with unstable angina pectoris subjects with class iii/iv cardiovascular disability according to the new york heart association classification 6. subjects have one kinds of tumors within 5 years 7. active hepatitis b (hbv dna\>1000copy/ml), hepatitis c or hiv infection. 8. subjects have an infectious diseases that cannot be controlled within 4 weeks 9. subjects have severe central nervous system disease or epilepsy 10. subjects are suffering from mental illness; patients with alcohol dependence, drug abuse, drug addiction, and medical, psychological or social conditions that may interfere with research or have an impact on the evaluation of research results 11. women in pregnancy (positive urine/blood pregnancy test) or lactation 12. subjects who have other conditions that were not appropriate for the group determined by the researchers.
perioperative care in ethiopia

Conditions: Perioperative Care

Summary: a national cross-sectional survey of surgery and anaesthesia at ethiopian public hospital facilities.

incorporating elements from recognized surgical and anesthesia facility assessment tools the survey assesses surgery and anaesthesia at ethiopian public hospital facilities. the surveys assesses infrastructure, workforce, and availability of resources across all national facilities providing surgery. an online national cross-sectional survey, designed through a consultative process involving senior clinicians - anesthesia providers, surgeons, and obstetricians. elements incorporated from existing tools, including the safe surgery hospital assessment tool, world federation of societies of anaesthesiologists (wfsa) anaesthesia facility assessment tool and the lancet commission on global surgery surgical assessment tool. survey questions grouped into themes: infrastructure, human resources, service delivery, and the availability of medications, equipment, and guidelines. the final quantitative survey includes 77 questions, for distribution to clinicians at a convenience sample of government hospitals providing major surgical services. private facilities are excluded. the online survey link sent via the n4pcc collaborator network to clinicians at each site. all collaborators and clinicians are perioperative practitioners (anesthesia providers, surgeons, obstetricians, nurses) at their respective institutions. additional facilities with no n4pcc collaborator contacted via the department of anesthesia at each institution. telephone follow-up with non-responding hospitals to overcome barriers to completion, including assistance with data input where required.

Eligibility criteria:
inclusion criteria: clinicians working at facilities providing perioperative care clinicians working in surgery, anaesthesia or obstetrics these will be recruited to provide data on perioperative capacity at all facilities providing surgery nationally exclusion criteria: clinicians working out-with perioperative care facilities not providing surgical services